Aetion: NEC Corporation and Aetion Announce Collaboration to Further Drug Development in Life Sciences Companies in Japan

NEC Orchestrating Future Fund, an ecosystem-based corporate venture capital (CVC) fund established in 2021 by NEC Corporation, announced that NEC and Aetion are collaborating to use real-world data (RWD) from Japanese electronic health records (EHR) on Aetion's Substantiate application, powered by the Aetion Evidence Platform (AEP), to further drug development in life sciences companies in Japan, and ultimately worldwide. NEC is a global leader in communications and information technology solutions and one of Japan's largest EHR vendors providing more than 50 years of IT services to hospitals across the country. It aims to address medical and healthcare challenges and create new value through its healthcare and life sciences business. The partnership between NEC and Aetion has the potential to improve the efficiency of the drug development process, streamline regulatory approval pathways and lead to the creation of new treatment methods. NEC Orchestrating Future Fund, an ecosystem-based corporate venture capital (CVC) fund established in 2021 by NEC Corporation, announced that NEC and Aetion are collaborating to use real-world data (RWD) from Japanese electronic health records (EHR) on Aetion's Substantiate application, powered by the Aetion Evidence Platform (AEP), to further drug development in life sciences companies in Japan, and ultimately worldwide. NEC is a global leader in communications and information technology solutions and one of Japan's largest EHR vendors providing more than 50 years of IT services to hospitals across the country. It aims to address medical and healthcare challenges and create new value through its healthcare and life sciences business. The partnership between NEC and Aetion has the potential to improve the efficiency of the drug development process, streamline regulatory approval pathways and lead to the creation of new treatment methods.